We created Bionanomatrix™ a peptide-based nanomaterial which promotes healing & improves outcomes following med device implantation & other procedures. We develop apps for the Bionanomatrix™ then partner with med device companies whose tech could benefit
https://t.co/RgQVpoTKId
A structured approach to biotech investing: scalable platform upside, with individual assets advancing toward clearly defined outcomes and exits. Learn more > https://t.co/p64IvQXKeZ
Coronary stents enhanced with Bionanomatrix™ promote improved vessel recovery, reducing the risks of thrombosis and restenosis. Read more on our pipeline > https://t.co/R9nNBP6ImU
Launching later this year: our first spinout! Endomimetics® is now an IP Foundry, fast-tracking patient access to our proprietary Bionanomatrix™ technology through specialized companies. First focus: improving dialysis vascular access and outcomes for patients worldwide.
Arteriovenous Fistula (AVF) remains the standard access for dialysis but high failure rates continue to impact clinical outcomes. Bionanomatrix™ is designed to support maturation and improve longevity by reducing complications. Learn more > https://t.co/I6tSflfv00
Engineered to work with the body, its biomimetic design promotes healing, reduces inflammation, and supports tissue integration. Learn more about the science behind Bionanomatrix™ >>> https://t.co/I6tSflfv00
Two ways to invest in the Endomimetics IP Foundry:
• Platform access to the Bionanomatrix™ portfolio
• Application-focused investments with clear milestones
Learn more: https://t.co/HLOoKOdYAU
Bionanomatrix™ mimics the body’s natural environment to reduce inflammation, inhibit clot formation, and support healthier healing. Learn more> https://t.co/I6tSflfv00
Endomimetics® CEO, Dr. Joseph Garner, shares an overview of our proprietary Bionanomatrix™ technology and what we need to fuel our next phase of growth.
Just announced! We are excited to share that Endomimetics® has restructured into an IP Foundry business model. Read more about what this means for our pipeline. > https://t.co/zzSE1Fdwmn
Bionanomatrix™ is engineered for real clinical impact across vascular, cardiovascular, orthopedic, dental, and neuro applications—helping enhance healing and improve patient outcomes.
Learn more: https://t.co/R9nNBP6ImU
Bionanomatrix™ delivers nitric oxide directly to tissues, continuously and precisely. Learn more about the many applications of Bionanomatrix >>> https://t.co/I6tSflg2Py
Bionanomatrix™, our proprietary technology, is shaping the future of healing and recovery with potential applications across a variety of specialties. Follow and discover more about Bionanomatrix today > https://t.co/I6tSflfv00
What if healing could happen differently? At Endomimetics®, our Bionanomatrix™ technology is paving the way. Follow to learn more and visit us at https://t.co/XDpQYLKmDB
In today’s episode, Dr. Sheeler takes on the ultimate challenge: picking the right bacterial colony from glycerol stock. Many colonies will grow—but only the one with the plasmid will make the cut.
https://t.co/SeBjrAVA29
We’re just 1 week away from Cracking the Code! Don’t miss the chance to watch this riveting documentary & hear from our expert panel as they discuss the future of biotech in Birmingham.
https://t.co/rq02MmLeFL
Dr. Sheeler is back & in this episode; he's continuing the series on isolating plasmid DNA. Will Dr. Sheeler get overnight growth?!? Will Dr. Sheeler get the plasmid?!? Check out the full video below for the results!
https://t.co/OiZm5FRY1o
Biotech’s Fall 2025 newsletter has officially landed in inboxes! Full of program updates, highlights, & future events, it’s a great way to stay involved.
Want to join the mailing list? Email us at [email protected] & we’ll add you!